Department of Neurosurgery, Gangnam Severance Hospital, Yonsei University College of Medicine, Seoul, Republic of Korea.
Department of Radiology, Gangnam Severance Hospital, Yonsei University College of Medicine, Seoul, Republic of Korea.
Acta Neurochir (Wien). 2022 Jun;164(6):1627-1634. doi: 10.1007/s00701-022-05110-3. Epub 2022 Jan 10.
Severe intracranial atherosclerotic stenosis (ICAS) is a major cause of stroke. Although percutaneous transluminal angioplasty and stenting (PTAS) treatment methods have increased over the last decade as alternative therapies, there is debate regarding the best method of treatment, with medical and surgical therapies often suggested.
We analyzed the long-term follow-up results from 5 years of intracranial stenting for intracranial stenosis from three stroke centers. The primary endpoints were early stroke complications or death within 30 days after stent insertion, and the secondary endpoint was a recurrent stroke between 30 days and 60 months. Correlating factors and Kaplan-Meier survival curves for recurrent stroke and in-stent restenosis (ISR) were also obtained.
Seventy-three PTAS in 71 patients were examined in this study. The primary and secondary endpoints were all 8.2% (n = 6), and restenosis was 13.7% (n = 10) during the 5-year follow-up. The primary endpoints were significantly frequent in the high National Institutes of Health Stroke Scale (NIHSS) and early stent (≤ 7 days after dual antiplatelet medication) groups. Secondary endpoint and ISR were identically frequent in the younger age group and in the presence of tandem stenosis in other major intracranial arteries. The cumulative probability of recurrent stroke and ISR at 60 months was 16.4% and 14.1%, respectively.
This study shows that PTAS is safe and effective for major ICAS. Reducing the early complication rate is still an important factor, despite the fact that long-term stroke recurrence was low.
严重颅内动脉粥样硬化狭窄(ICAS)是中风的主要原因。尽管经皮腔内血管成形术和支架置入术(PTAS)作为替代疗法在过去十年中有所增加,但对于最佳治疗方法仍存在争议,通常建议采用药物和手术治疗。
我们分析了来自三个中风中心的五年颅内狭窄支架置入术的长期随访结果。主要终点是支架置入后 30 天内的早期中风并发症或死亡,次要终点是 30 天至 60 个月之间的复发性中风。还获得了相关因素和支架内再狭窄(ISR)的 Kaplan-Meier 生存曲线。
本研究共检查了 71 例 73 例 PTAS。主要和次要终点均为 8.2%(n=6),5 年随访时再狭窄为 13.7%(n=10)。高国立卫生研究院中风量表(NIHSS)和早期支架(双抗血小板治疗后≤7 天)组的主要终点明显更常见。次要终点和 ISR 在年龄较小的组中以及在其他主要颅内动脉中存在串联狭窄的情况下同样常见。60 个月时复发性中风和 ISR 的累积概率分别为 16.4%和 14.1%。
本研究表明,PTAS 治疗主要 ICAS 是安全有效的。尽管长期中风复发率较低,但降低早期并发症发生率仍然是一个重要因素。